Masimo Corporation
Precision Patient Monitoring
Irvine, California, United States
Masimo Corporation specializes in pulse oximetry, patient monitoring, and AI-enabled monitoring solutions for acute care settings. The company is set to be acquired by Danaher for $9.9 billion.
How We Help
Problem Statement
Masimo addresses the critical need for accurate, reliable, and continuous noninvasive patient monitoring, especially in challenging clinical conditions involving patient motion or low perfusion, to improve patient safety and clinical decision-making across various healthcare settings.
Core Technology
Pulse oximetry, patient monitoring, AI-enabled monitoring solutions
Key Differentiators
Proprietary and patented Signal Extraction Technology (SET®) pulse oximetry, clinical efficacy and reputation (often considered a 'gold standard'), high switching costs for hospitals, continuous innovation, integrated platform approach.
Clinical Focus
Noninvasive patient monitoring across intensive care units, neonatal intensive care units, operating rooms, post-surgical wards, emergency medical services, physician offices, long-term care facilities, and home care. Key areas include pulse oximetry, blood constituent monitoring, brain function monitoring, respiratory monitoring, patient safety, and remote patient monitoring.
Target Customers
Hospitals, intensive care units, neonatal intensive care units, operating rooms, post-surgical wards, emergency medical services, physician offices, long-term care facilities, home care providers, and OEM partners.
Product Stage
Mature
Company Info
- Business Model
- B2B, razor-and-blade model, direct sales, OEM partnerships
- Founded
- 1989
- Total Funding
- 9,900,000,000
- Website
- www.masimo.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Masimo's technology boasts clinical efficacy and a reputation as a 'gold standard' in patient monitoring. Its solutions are clinically proven to improve patient safety, including reducing severe retinopathy of prematurity in neonates and aiding critical congenital heart disease screening.
IP Protection
Proprietary and patented technology, specifically Signal Extraction Technology (SET®) pulse oximetry.
MedStartr Index Score
?What do you think of Masimo Corporation?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.